• Silo Wellness (SILO) has signed a multi-year licensing agreement with the family of global reggae icon Bob Marley
  • The Marley One product line will include a range of functional mushroom tinctures each offering unique health and wellness benefits
  • Silo plans to add additional functional mushroom products including gummies, capsules and cosmetics
  • Silo Wellness is a holding company focused on functional mushroom and psychedelic opportunities
  • Silo Wellness Inc. (SILO) opened trading at C$0.17 per share

Silo Wellness (SILO) has announced the launch of Marley One, the first global functional and psychedelic mushroom consumer brand.

The initial product offering will include a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica, including species such as cordyceps, lion’s mane, chaga, reishi and turkey tail.

Each offers a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement.

The company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics.

In March, Silo Wellness announced a multi-year licensing agreement with the family of global reggae icon Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms.

“Today is a significant milestone for our company as we introduce the world to Marley One, a portfolio of branded mushroom products with instant name recognition and global visibility honoring Bob Marley’s legacy and connection to nature and plant-based wellbeing,” said Silo Wellness CEO Douglas K. Gordon.

“We are building what will become the world’s first global functional and psychedelic mushroom brand, guided by our vision to help people achieve healthier, more fulfilling lives and become the best versions of themselves.”

“We know Bob would be proud of what we’re building with Silo Wellness and the Marley One brand,” said Rita Marley. “Our family has always revered the ancient history and transformative potential of nature’s gifts.”

The initial Marley One product line includes:

  • One Mind : A coffee-flavored blend of lion’s mane and L-theanine designed to improve focus and cognitive function.
  • One Flow : A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function.
  • One Harmony : A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion.
  • One Body : A berry-flavored blend of turkey tail and astragalus designed to support immune health.
  • One Rest : A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep.

Founded in 2018, Silo Wellness is a ‘spore-to-door’ vertically integrated company and the leading psilocybin cultivator and facilitator of psychedelic retreats in Jamaica, a jurisdiction where the cultivation, extraction, and consumption of psilocybin mushrooms is permissible.

In 2019, the company announced a patent-pending psilocybin nasal spray. In addition to its market-leading mushroom and psilocybin products, Silo Wellness conducts ketamine-assisted retreats in Oregon and recently expanded its psychedelic offerings to introduce 5-MeO-DMT-enhanced retreats across Jamaica.

Said Cedella Marley, CEO of Bob Marley Group of Companies,

“As a family, we seek to use our platform to inspire positive change, and the launch of the Marley One mushroom brand, in collaboration with a pioneering company like Silo Wellness, allows us to do just that by marrying ancient wisdom with modern science. It’s our wish that these products will empower people to experience oneness with nature and the universe at large – and ultimately, achieve greater self-actualization.”

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership.

Silo Wellness Inc. (SILO) opened trading at C$0.17 per share.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.